Survivin gene promoter -31 G/C polymorphism is associated with wilms tumor susceptibility in Serbian children

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 8, 2012, Pages

  Radojevic Skodric, Sanja ^a   Basta Jovanovic, Gordana ^a   Brasanac, Dimitrije ^a   Nikolic, Nadja ^b   Bogdanovic, Ljiljana ^a   Milicic, Biljana ^b   Milasin, Jelena ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

nephroblastoma; PCR RFLP; risk factor; single nucleotide polymorphism; survivin gene

Indexed keywords

CYSTEINE; GLYCINE; SURVIVIN;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHILD; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; NEPHROBLASTOMA; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD; SERBIA; SURVIVIN GENE;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; INHIBITOR OF APOPTOSIS PROTEINS; KIDNEY NEOPLASMS; MALE; PROGNOSIS; SERBIA; WILMS TUMOR;

EID: 84868647244     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31825d3076     Document Type: Article

References (32)

1. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Miscrosc. 2001;34:207-212.
2. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev. 1999;13:239-252.
3. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-584.
4. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 2001;7:542-547.
5. Melet A, Song K, Bucur O, et al. Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol. 2008;615:47-79.
6. Wang YH, Yeh SD, Shen KH, et al. A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma. Toxicol Appl Pharmacol. 2009;241:111-118.
7. Gazouli M, Tzanakis N, Rallis G, et al. Survivin 31 G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 2009;24:145-150.
8. Cheng ZJ, Hu LH, Huang SJ. Correlation of 31 G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma. Ai Zheng. 2008;27:258-263.
9. Jang JS, Kim KM, Kang KH, et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 2008;60:31-39.
10. Kalapurakal JA, Nan B, Norkool P, et al. Treatment outcomes in adults with favourable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group. Int J Radiat Oncol Biol Phys. 2004;60:1379-1384.
11. Hartman DJ, MacLennan G. Wilms tumor. J Urol. 2005;173: E2147.
12. Gommersall LM, Arya M, Mushtaq I, et al. Current challenges in Wilms' tumor management. Nat Cli Pract Oncol. 2005;2: 298-304.
13. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet. 2006;15:R196-R201.
14. Huff V. Wilms' tumours: About tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer. 2011;11: 111-121.
15. Koesters R, Ridder R, Kopp-Schneider A, et al. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res. 1999;59:3880-3882.
16. Rivera MN, Kim WJ, Wells J, et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007;315:642-645.
17. Williams RD, Al-Saadi R, Chagtai T, et al. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin Cancer Res. 2010;16:2036-2045.
18. Vujanic MG, Sandstedt B, Harms D, et al. Revised International Society of Pediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol. 2002;38:79-82.
19. Yang L, Zhu H, Zhou B, et al. The association between the survivin C31 G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci. 2009;54:1021-1028.
20. Xu Y, Fang F, Ludewig G, et al. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004;23:527-537.
21. Borbely AA, Murvai M, Szarka K, et al. Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol. 2007;60:303-306.
22. Wagner M, Schmelz K, Dorken B, et al. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res. 2008;32:1054-1060.
23. Bayram S, Akkiz H, Bekar A, et al. The association between the survivin 31 G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol. 2011;35:555-559.
24. Kawata N, Tsuchiya N, Horikawa Y, et al. Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer. 2011;129:1872-1880.
25. Miller MA, Karacay B, Breslow HE, et al. Prognostic value of quantifying apoptosis factor expression in favorable histology Wilms tumors. J Pediatr Hematol Oncol. 2005;27:11-14.
26. Miller MA, Ohashi K, Zhu X, et al. Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: A report from the children's oncology group. J Pediatr Hematol Oncol. 2006;7:412-417.
27. Yang X, Xiong G, Chen X, et al. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135: 1341-1349.
28. Han CH, Wei Q, Lu KK, et al. Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. Int J Clin Exp Med. 2009;2:289-299.
29. Jaiswal PK, Goel A, Mandhani A, et al. Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep. 2012;39:5615-5621.
30. Hennig G, Gehrmann M, Stropp U, et al. Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both singlenucleotide polymorphisms and mRNA expression. Clin Chem. 2010;56:1845-1853.
31. Weiss JR, Baer MR, Ambrosone CB, et al. Pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia. Cancer Epidemiol Biomarkers Prev. 2007;16:1038-1041.
32. Ferrara M, Capozzi L, Russo R. Impact of the MTHFR C677T polymorphism on risk of Wilms tumor: Casecontrol study. J Pediatr Hematol Oncol. 2009;4:256-258.